Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype
Authors:
- 1 November 2011
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 219 (1) , 240-244
Abstract
No abstract availableKeywords
Funding Information
- JDRF
- BSF
- NIH (RO1DK085226)
This publication has 29 references indexed in Scilit:
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisNew England Journal of Medicine, 2011
- Haptoglobin Genotype Is Predictive of Major Adverse Cardiac Events in the 1-Year Period After Percutaneous Transluminal Coronary Angioplasty in Individuals With DiabetesDiabetes Care, 2003
- Genetically Determined Heterogeneity in Hemoglobin Scavenging and Susceptibility to Diabetic Cardiovascular DiseaseCirculation Research, 2003
- Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trialsThe Lancet, 2003
- Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetesJACC, 2002
- Structure-function analysis of the antioxidant properties of haptoglobinBlood, 2001
- Vitamin E Supplementation and Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.Journal of Clinical Investigation, 1995
- The oxidation hypothesis of atherosclerosisThe Lancet, 1994
- Haptoglobin: The Evolutionary Product of Duplication, Unequal Crossing Over, and Point Mutation1982